Dynavax Technologies (DVAX) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Company positioning and strategy

• Focused on commercial-stage vaccines leveraging novel adjuvant technology to enhance immune response, with a key inflection point driven by lead asset growth and pipeline advancement.

• Balanced approach to expanding earnings from lead asset while generating value from emerging pipeline and maintaining financial flexibility for business development.

• Strong commercial execution and adaptability, especially in the retail segment, underpin market share gains.

• Risk management and late-stage focus differentiate the company from peers, with a strategy centered on de-risked assets and proven biology.

• Revenue guidance for the year is $315–$325 million, reflecting continued growth and financial discipline.

HEPLISAV-B performance and market dynamics

• HEPLISAV-B benefits from a differentiated profile: two doses over one month versus three doses over six months for competitors, with higher seroprotection rates.

• ACIP's 2022 recommendation for universal adult hepatitis B vaccination expanded the addressable market, supporting both market growth and share gains.

• Leading market share in retail, exiting Q2 with just under 60%, and retail is projected to double to 50% of the adult Hep B market by 2030.

• Recent Medicare reimbursement access unlocks further growth potential in the retail segment, especially from 2026 onward.

• Four key market segments: IDN, retail, dialysis, and other, with primary growth focus on IDN and retail.

Retail channel expansion and strategy

• Retail segment expected to reach 50% of the adult Hep B market by 2030, with potential for faster growth depending on market dynamics.

• Strategic investments in retail marketing channels, including in-store and digital awareness campaigns, to drive patient demand and support product uptake.

• High share in retail and ability to capture patients transitioning from other segments position the company for continued growth.